Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Terminated 2Completed 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Melanoma 5Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Stomach Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Small Cell Lung Cancer Recurrent 1Safety Issues 1Recurrent Liver Cancer After Liver Transplantation 1Recurrence 1Radiation Pneumonitis 1Ovarian Neoplasms 1Neoplasms, Squamous Cell 1Neoplasm Metastasis 1Lymphoma 1Lung Neoplasms 1Locally Advanced or Metastatic Solid Tumors 1Liver Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1

Interventions

durvalumab 2avelumab 2atezolizumab 2Nivolumab 2pembrolizumab 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1daromun 1cemiplimab 1advexin 1Sampling Studies 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Merkel Cell × atezolizumab × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡